Deacylation of echinocandin B by Actinoplanes utahensis.
- 1 January 1989
- journal article
- research article
- Published by Japan Antibiotics Research Association in The Journal of Antibiotics
- Vol. 42 (3) , 382-388
- https://doi.org/10.7164/antibiotics.42.382
Abstract
Echinocandin B (ECB) is a lipopeptide antifungal agent produced by several species of Aspergillus. The lipid side chain of cyclic lipopeptides is known to be an important determinant of their antibiotic activity and toxicity. Deacylation of another lipopeptide antibiotic, A21978C, had formerly been accomplished with Actinoplanes utahensis. In spite of the structural dissimilarities between the peptide cores and acyl side chains of A21978C and ECB, A. utahensis also removed the linoleoyl acyl unit from the amino terminus of ECB to yield the bioinactive cyclic peptide core, or "nucleus". The ECB nucleus, which contained a new titratable group at the N-terminus, was subsequently employed for chemical reacylation with other side chains to yield of novel ECB analogs. One of these, cilofungin (LY121019), containing an N-(4-n-octyloxybenzoyl)acyl unit, is currently undergoing clinical evaluation.This publication has 4 references indexed in Scilit:
- Synthesis of new analogs of echinocandin B by enzymatic deacylation and chemical reacylation of the echinocandin B peptide: Synthesis of the antifungal agent cilofungin (LY121019).The Journal of Antibiotics, 1989
- Enzymatic and chemical modifications of lipopeptide antibiotic A21978C: The synthesis and evaluation of daptomycin (LY146032).The Journal of Antibiotics, 1988
- Deacylation of A21978C, an acidic lipopeptide antibiotic complex, by Actinoplanes utahensis.The Journal of Antibiotics, 1987
- In vitro and in vivo anti-Candida activity and toxicology of LY121019.The Journal of Antibiotics, 1984